X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

UPDATE 3-Drug maker Novo Nordisk to build $78 mln plant in Iran

Yuvraj_pawp by Yuvraj_pawp
5th October 2015
in Facilities & Operation

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Danish drug maker Novo Nordisk will invest 70 million euros ($78 million) to build a manufacturing plant in Iran, joining a small group of European companies to announce concrete deals there since the Islamic Republic reached a nuclear deal in July.

Novo Nordisk, the world’s largest diabetes drugs maker, has had a subsidiary in the country since 2005 selling insulin and employing 130 people.

But the plant “signals our long-term commitment to Iran”, the Danish company said in a statement.

“We have been working on this for a long time, also before the nuclear agreement was settled, and we have confidence that the Iranian society and economy is developing positively,” Ole Moelskov Bech, head of the firm’s Near East unit, told Reuters.

Construction is expected to begin in six months’ time, the company said.

The medicinal sector has escaped U.S., European Union and United Nations sanctions, which have focused on industries that could be related to nuclear activity as well as on banking, technology and oil.

But the restrictions have nevertheless made doing business in Iran tricky, Bech said.

“Even though the medicine industry was never abandoned in Iran (by foreign businesses), the sanctions have been making it all much more difficult as a lot of rules needed to be followed, on information technology and banking, which made it necessary to have individual systems for Iran,” Bech told Reuters.

Novo Nordisk has not been able to use the same IT platforms as in the rest of the business, forcing the company to spend time on work-around solutions, Bech said.

Several European ministers have visited Iran with businesses in tow since it struck the deal with six world powers in July under which it must curb sensitive aspects of its nuclear energy programme in exchange for a lifting of sanctions.

Earlier this month, Austrian companies signed deals worth 80 million euros with Iranian partners.

But most Western companies say they will wait until the nuclear agreement is implemented and sanctions removed before they make any firm business commitments in Iran.

Copenhagen Airport A/S said on Tuesday the first flights between Denmark and Iran would begin in March 2016, resuming a direct service between the capitals that had been suspended for eight years.($1 = 0.8950 euros) ($1 = 6.6867 Danish crowns)

Previous Post

Allergan Successfully Completes Kythera Acquisition; Adds Game-Changing KYBELLA Treatment for Double-Chin

Next Post

Hillary Clinton Proposes $250 Monthly Cap on Prescription Drug Costs

Related Posts

API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
API Manufacturing Facility
Americas

Lilly to Build $6.5B API Manufacturing Facility in Houston

25th September 2025
Merck and Siemens
Drug Development

Merck and Siemens to Accelerate AI Driven Drug Development

24th September 2025
Scottish Pharma Sector
Europe

ABPI Launches Manifesto to Advance Scottish Pharma Sector

23rd September 2025
Automating Experimental Design with Generative AI in Pharma
Facilities & Operation

Automating Experimental Design with Generative AI in Pharma

20th September 2025
Next Post

Hillary Clinton Proposes $250 Monthly Cap on Prescription Drug Costs

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In